These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31746520)

  • 1. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
    Sugimori M; Sugimori K; Tsuchiya H; Suzuki Y; Tsuyuki S; Kaneta Y; Hirotani A; Sanga K; Tozuka Y; Komiyama S; Sato T; Tezuka S; Goda Y; Irie K; Miwa H; Miura Y; Ishii T; Kaneko T; Nagahama M; Shibata W; Nozaki A; Maeda S
    Cancer Sci; 2020 Jan; 111(1):266-278. PubMed ID: 31746520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
    Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
    J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.
    Leick KM; Tomanek-Chalkley A; Coleman KL; Chan CHF
    Ann Surg Oncol; 2023 Oct; 30(11):6652-6660. PubMed ID: 37303025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
    Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
    Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma.
    Labiano I; Huerta AE; Alsina M; Arasanz H; Castro N; Mendaza S; Lecumberri A; Gonzalez-Borja I; Guerrero-Setas D; Patiño-Garcia A; Alkorta-Aranburu G; Hernández-Garcia I; Arrazubi V; Mata E; Gomez D; Viudez A; Vera R
    Sci Rep; 2024 Jul; 14(1):16203. PubMed ID: 39003322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Multiplex Detection of
    Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
    Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens.
    Sho S; Court CM; Kim S; Braxton DR; Hou S; Muthusamy VR; Watson RR; Sedarat A; Tseng HR; Tomlinson JS
    PLoS One; 2017; 12(1):e0170897. PubMed ID: 28125707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis.
    Wei T; Zhang J; Li J; Chen Q; Zhi X; Tao W; Ma J; Yang J; Lou Y; Ma T; Li X; Zhang Q; Chen W; Que R; Gao S; Bai X; Liang T
    Mol Oncol; 2020 Sep; 14(9):1966-1977. PubMed ID: 32593194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.